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Ras oncogene-independent activation of RALB signaling is a
targetable mechanism of escape from NRAS(V12) oncogene
addiction in acute myeloid leukemia
EJ Pomeroy1, LA Lee1, RDW Lee1, DK Schirm1, NA Temiz2, J Ma3, TA Gruber3,4, E Diaz-Flores5, BS Moriarity2,6, JR Downing3,
KM Shannon5, DA Largaespada2,6,7 and CE Eckfeldt1,2
Somatic mutations that lead to constitutive activation of NRAS and KRAS proto-oncogenes are among the most common in human
cancer and frequently occur in acute myeloid leukemia (AML). An inducible NRAS(V12)-driven AML mouse model has established a
critical role for continued NRAS(V12) expression in leukemia maintenance. In this model genetic suppression of NRAS(V12)
expression results in rapid leukemia remission, but some mice undergo spontaneous relapse with NRAS(V12)-independent (NRI)
AMLs providing an opportunity to identify mechanisms that bypass the requirement for Ras oncogene activity and drive leukemia
relapse. We found that relapsed NRI AMLs are devoid of NRAS(V12) expression and signaling through the major oncogenic Ras
effector pathways, phosphatidylinositol-3-kinase and mitogen-activated protein kinase, but express higher levels of an alternate Ras
effector, Ralb, and exhibit NRI phosphorylation of the RALB effector TBK1, implicating RALB signaling in AML relapse. Functional
studies confirmed that inhibiting CDK5-mediated RALB activation with a clinically relevant experimental drug, dinaciclib, led to
potent RALB-dependent antileukemic effects in human AML cell lines, induced apoptosis in patient-derived AML samples in vitro
and led to a 2-log reduction in the leukemic burden in patient-derived xenograft mice. Furthermore, dinaciclib potently suppressed
the clonogenic potential of relapsed NRI AMLs in vitro and prevented the development of relapsed AML in vivo. Our findings
demonstrate that Ras oncogene-independent activation of RALB signaling is a therapeutically targetable mechanism of escape
from NRAS oncogene addiction in AML.
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INTRODUCTION
Despite aggressive combination chemotherapy, the majority of
patients with acute myeloid leukemia (AML) die of relapsed
treatment refractory disease.1 Furthermore, a large number of
older and/or unfit AML patients cannot tolerate intensive
treatment approaches and are cured o10% of the time.1 The
disappointing outcomes with conventional treatment approaches
for AML have driven intense interest in safer and more effective
targeted treatment approaches. While the genetic landscape of
AML has been extensively characterized, genetically based
targeted therapies have yet to be realized and the optimal
therapeutic target(s) are not known.2,3
RAS proto-oncogenes are mutated in about 10–15% of human
AML, and additional recurring AML mutations rely on Ras signaling
for their oncogenic effects (that is, PTPN11, NF1, FLT3-ITD and KIT).3–6
A critical role for oncogenic Nras and Kras in leukemogenesis and
maintenance of AML cells has been substantiated in genetically
engineered mouse models.7–10 Furthermore, the mitogen-
activated protein kinase (MAPK) and phosphatidylinositol-3-
kinase (PI3K) pathways downstream of Ras have been shown to
regulate leukemic stem cell self-renewal in AML.11 In fact,
the MAPK and PI3K pathways are active in the majority of
patient-derived AML samples, further supporting a key role for Ras
signaling in AML maintenance.12,13
Oncogenic RAS mutations are among the most common
molecular alterations in human cancer, and thus Ras has been
the focus of intense interest for drug development.14 A major
obstacle for targeted cancer treatment approaches has been the
almost ubiquitous development of treatment resistance. For
example, disruption of the post-translational modification of Ras
with farnasyltransferase inhibitors demonstrated encouraging
preclinical activity, but their clinical activity has been limited
owing to resistance conferred by alternative biochemical path-
ways for the prenylation of Ras.15 Targeting BRAF and/or MEK has
shown encouraging responses for BRAF(V600E) mutant non-small-
cell lung cancer and melanoma, but responses have been variable
and transient owing to treatment resistance.16–20 It has become
clear that diverse mechanisms such as disruption of drug–target
interaction, mutations or amplifications that lead to activation of
downstream signaling pathways, and/or activation of alternative
growth and survival pathways can lead to resistance to most, if
not all, targeted cancer therapies.21,22 Therefore, a better under-
standing of disease and context-specific resistance mechanisms
1Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, University of Minnesota, Minneapolis, MN, USA;
2Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; 3Department of Pathology, St Jude Children’s Research Hospital, Memphis, TN, USA; 4Department of
Oncology, St Jude Children’s Research Hospital, Memphis, TN, USA; 5Department of Pediatrics, University of California, San Francisco, CA, USA; 6Department of Pediatrics, Division
of Hematology and Oncology, Minneapolis, MN, USA and 7Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN, USA.
Correspondence: Dr CE Eckfeldt, Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, University of
Minnesota, 420 Delaware Street SE, MMC 480, PWB 14-242, Minneapolis MN 55455, USA.
E-mail: eckf0002@umn.edu
Received 26 July 2016; revised 17 October 2016; accepted 7 November 2016; published online 19 December 2016
Oncogene (2017) 36, 3263–3273
www.nature.com/onc
will be essential to develop rational combination strategies for
specific diseases.
To model Ras oncogene-targeted therapy for AML, we used a
tetracycline-repressible NRAS(V12) and Mll-AF9-driven AML geneti-
cally engineered mouse model (tNM AML).8 The leukemia cells in
this model are NRAS(V12)-dependent (NRD), and suppressing NRAS
(V12) expression leads to rapid remission in leukemic mice, further
highlighting the clinical potential of targeting oncogenic NRAS in
AML.8 This model faithfully recapitulates the key challenge for
clinically targeted cancer treatment, in that some mice sponta-
neously relapse with NRAS(V12)-independent (NRI) AML, providing
a robust tool to study the mechanisms of relapse after Ras
oncogene-targeted therapy. We interrogated key cancer signaling
pathways, performed global gene expression analysis and
performed functional studies to identify mechanisms that drive
relapse with NRI AML and provide insight into the rational
development of novel targeted treatment approaches for AML.
RESULTS
Suppressing Ras oncogene expression in NRAS(V12)-driven AML
leads to spontaneous relapse with NRI disease
We leveraged the tNM AML model to investigate potential
mechanisms of relapse after targeting the Ras oncogene in
AML.8 In this system, suppression of NRAS(V12) expression resulted
in rapid leukemia regression (Figure 1). Notably, some mice
spontaneously relapsed with NRI AMLs despite continued Dox
treatment (Figure 1). Relapsed NRI AMLs were harvested for
further characterization (relapsed NRI1 and NRI2 AMLs).
We confirmed NRAS oncogene independence of relapsed NRI
AMLs by transplanting NRI1 and NRI2 AMLs into secondary
recipients. Unlike the parental de novo NRD AML, relapsed NRI1
and NRI2 AMLs did not regress after in vivo Dox treatment, and
mice rapidly succumbed from progressive leukemia (Figure 2a).
Similarly, ex vivo treatment of leukemia cells with Dox potently
suppressed the clonogenic potential of de novo NRD but
not relapsed NRI1 or NRI2 AMLs (Figure 2b). Western blotting
excluded the possibility of aberrant re-expression of NRAS(V12) in
relapsed NRI AMLs in the presence of Dox treatment, thereby
confirming the NRAS(V12) independence of the relapsed NRI AMLs
(Figure 2c).
Analysis of cancer signaling pathways in de novo NRD and
relapsed NRI AMLs
To investigate potential mechanisms that drive AML relapse after
suppressing oncogenic Ras, we performed flow cytometric and
reverse-phase protein array (RPPA) analyses of key cancer
signaling pathways. Flow cytometric analysis confirmed a
decrease in canonical oncogenic Ras effector signaling pathways
—MAPK and PI3K—with decreased levels of phosphorylated ERK
and AKT following Dox-mediated suppression of NRAS(V12) in
both de novo NRD and relapsed NRI AML cells (Figure 3a).
Phosphorylation of TBK1, a key target of RALB signaling, was
decreased after Dox-mediated NRAS(V12) suppression in de novo
NRD AML, but was maintained at higher levels in relapsed NRI
AMLs, even in the absence of NRAS(V12) expression (Figure 3a).
The expression of BCL-xL and BCL2 proteins, which are established
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Figure 1. Spontaneous relapse after suppression of Ras oncogene
expression in mice with NRAS(V12)-driven AML. White blood cell
(WBC) counts of leukemic SCID beige mice with NRAS(V12)-
dependent (NRD) AML rapidly decline after doxycycline (Dox)-
mediated suppression of NRAS(V12) expression. Two of five mice
spontaneously relapsed with NRI AML (NRI1 and NRI1 AMLs) despite
continued Dox treatment.
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Figure 2. Relapsed NRI AMLs are resistant to doxycycline (Dox)-
mediated suppression of NRAS(V12) expression and do not
re-express oncogenic NRAS protein. (a) NRI1 or NRI2 AML cells
were transplanted in secondary SCID beige recipient mice. NRI AMLs
continued to grow in secondary recipients despite Dox treatment,
and mice rapidly succumbed to progressive leukemia. (b) NRI1 or
NRI2 AML cells harvested from the spleens of leukemic mice were
treated ex vivo with 1 μg/ml Dox for 48 h and then plated in
leukemia colony-forming cell (L-CFC) assays. Results are presented
as L-CFC in Dox-treated relative to control treated AML cells (n= 3
independent experiments, error bars= 1 s.d., *Po0.001). (c) Western
blotting for NRAS protein in splenocytes harvested from mice with
NRD and NRI AMLs in the presence or absence of Dox as indicated.
NRI AMLs were generated and maintained in the presence of Dox to
prevent re-expression of NRAS(V12) or re-emergence of NRD AML, so
were not evaluated in the absence of Dox.
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targets of RALB-TBK1 signaling, were also maintained at higher
levels in relapsed NRI AMLs (Figure 3a and Supplementary
Figure S1). Proapoptotic proteins BIM, BAD and BAX were
expressed at lower levels in NRI AMLs (Supplementary
Figure S2), suggesting that an altered balance of pro- and
antiapoptotic proteins contributes to the survival of relapsed
NRI AML cells. There were no differences in the expression
levels or activation of other Ras effector proteins, oncoproteins or
tumor suppressor proteins that were evaluated (Supplementary
Figure S2).
We complemented our flow cytometric analysis by performing
RPPA analysis.23 Of the 292 epitopes interrogated, 27 showed
different levels of protein expression or phosphorylation between
Dox-treated NRD AML and relapsed NRI AMLs (Supplementary
Table S1 and Figure 3b). We observed lower levels of Ras-
associated proteins including PI3K p85, BRAF(p445), mTOR and
PKC βII(p660) in relapsed NRI AMLs compared with NRD AML.
Consistent with our flow cytometric analysis, relapsed NRI AMLs
also expressed lower levels of proapoptotic mediators BIM and
BAX. Relapsed NRI AMLs also had lower levels of CHK1(p296) and
increased levels of YAP and CDK1 compared with NRD AMLs.
Notably, YAP has been shown to mediate resistance to MAPK
targeted therapy and can reverse Kras oncogene addiction in a
Kras oncogene-driven pancreatic cancer model.24,25
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Figure 3. Comparison of canonical Ras effector and cancer signaling pathways in de novo NRD AML and relapsed NRI AMLs identifies potential
mechanisms that drive relapse with NRI disease. (a) Flow cytometry histograms of Ras effector pathways (left) or BCL2 and BCL-xL protein
levels (right) in splenocytes from leukemic mice with untreated NRD AML (red shaded), 72 h Dox-treated NRD AML (red open), NRI1 AML
(green open) or NRI2 AML (blue open). Signaling through canonical Ras effector pathways was determined by levels of phosphorylated AKT
(pAKT) for PI3K, phosphorylated ERK1/2 (pERK1/2) for MAPK and phosphorylated TBK1 (pTBK1) for RALB. Each histogram represents
splenocytes from an individual mouse. All mice with NRI AMLs were maintained on Dox to prevent re-expression of NRAS(V12). The median
fluorescence intensity for experimental groups is presented below the histograms for each protein of interest (error bars= 1 s.d., *Po0.05, NS,
nonsignificant P-value) (b) Heatmap of differential protein levels between Dox-treated de novo NRD and relapsed NRI AMLs as determined by
RPPA analysis (Benjamini–Hochberg-corrected q-value of ⩽ 0.05).
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Next-generation RNA sequencing of de novo NRD and relapsed
NRI AMLs
We then explored potential mechanisms driving the NRAS
oncogene independence of relapsed NRI AMLs using next-
generation RNA sequencing. We interrogated gene expression
and transcript characteristics of Dox-treated NRD cells and NRI
AMLs. This analysis identified 3606 transcripts that were differen-
tially expressed between both NRD vs NRI1 and NRD vs NRI2 AMLs
(Figure 4a). No consistent single-nucleotide variations, copy
number alterations by array comparative genomic hybridization
or fusion transcripts were identified other than the Mll-AF9 fusion
knock-in gene that is known to be present in both NRD and NRI
AMLs (data not shown).8 NRI1 and NRI2 AML cells were more
similar to each other than NRD AML cells as determined by
unsupervised clustering. Notably, NRI1 and NRI2 samples did not
segregate in unsupervised clustering based on all identified
transcripts (Figure 4b), suggesting that they may share a common
mechanism for NRI growth and survival.
We performed Ingenuity Pathway Analysis to identify enriched
cellular processes, signaling pathways and predicted upstream
regulators of differentially expressed genes (Supplementary
Tables S2 and S3). The Tec kinase pathway was among the most
activated pathways in relapsed NRI AMLs compared with de novo
NRD AML (z-score 4.333, P= 5.888 × 10− 6). Bruton’s tyrosine
kinase, a member of the Tec kinase family, has been identified
as a targetable pathway in AML.26–28 The PI3K signaling pathway
was the most inhibited pathway in relapsed NRI AMLs compared
with de novo NRD AML (z-score =− 3.087, P= 2.570 × 10− 5),
consistent with their decreased dependence on canonical Ras
signaling. The canonical nuclear factor-κB signaling pathway was
activated in relapsed NRI AMLs compared with de novo NRD AML
(z-score = 2.111, P= 1.479 × 10− 4) and NFKB1 was among the
predicted activated upstream regulators in relapsed NRI AML cells
(z-score = 2.603, P= 2.000 × 10− 4). Other predicted upstream
regulators that were activated in relapsed NRI AMLs included
HOXA9 (z-score = 2.865, P= 5.420 × 10− 7), CEBPA (z-score = 2.307,
P= 2.510 × 10− 12) and STAT3 (z-score = 2.084, P= 1.340 × 10− 10)
that have established roles in AML.29–31
Many transcriptional regulators were differentially expressed
between de novo NRD AML and relapsed NRI AMLs (Supplementary
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Figure 4. Next-generation sequencing analysis of de novo NRD AML and relapsed NRI AMLs. (a) Differential transcript levels between
splenocytes from leukemic mice with de novo NRD AML after 72 h of Dox treatment and relapsed NRI1 and NRI2 AMLs (n= 3 mice per group,
differential expression defined as Benjamini–Hochberg-corrected q-value of ⩽ 0.01- and 1.5-fold change). All mice with NRI AMLs were
maintained on Dox to suppress NRAS(V12) expression. (b) Hierarchical clustering of de novo NRD and relapsed NRI1 and NRI2 AMLs.
(c) Expression of RALB-associated transcripts that are enriched in both relapsed NRI AMLs compared to de novo NRD AML. Fold change
(NRI/NRD) is indicated and the Benjamini–Hochberg corrected q-value is ⩽ 0.01 for all transcripts.
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Table S4). The leukemogenic transcription factors Gfi1 and Myb
were among the most highly upregulated in relapsed NRI AMLs
compared with the de novo NRD AML. ID1, a transcriptional
regulator that cooperates with oncogenic Ras in the development
of metastatic breast cancer, was also upregulated in relapsed NRI
AMLs.32 Similar to flow cytometric and RPPA analyses, several
mediators of apoptosis were differentially expressed between de
novo NRD and relapsed NRI AMLs (Supplementary Figure S3).
Notably, relapsed NRI AMLs expressed lower levels of proapoptotic
Bim and higher levels of antiapoptotic Bcl2 transcripts.
To further investigate the role of RALB signaling as a mediator
of NRAS(V12) independence for relapsed NRI AMLs we evaluated
the differential expression of genes that are known to be
associated with RALB activation and signaling (Figure 4c). Notably,
Cdk5 and Rgl2, positive regulators or RALB activation, were both
enriched in relapsed NRI AMLs compared with de novo NRD
AML.33,34 Ralb was also upregulated in relapsed NRI AMLs, and
RALB effectors including components of the nuclear factor-κB
transcriptional complex, Nfkb1 and Rel, and prosurvival Bcl2 were
also enriched in relapse NRI AMLs compared with de novo NRD
AML. Other noncanonical IκB kinases, IκBKβ and IκBKε, were also
upregulated in relapsed NRI AMLs. Taken together, the differential
expression of RALB-associated proteins and genes support a key
role for RALB signaling in NRI AML relapse.
Inhibition of RALB activation with dinaciclib has potent
antileukemic effects on human AML cells in vitro
While clinically relevant direct Ras-like (Ral) inhibitors are lacking,
dinaciclib, a cyclin-dependent kinase inhibitor, has been shown to
inhibit CDK5-mediated activation of Ral signaling.33,35 We
evaluated the effects of dinaciclib on RALB signaling in AML cell
lines. In vitro treatment of human KG1 AML cells with dinaciclib
potently inhibited RALB activation, resulting in a dose-dependent
reduction in RALB-GTP levels (Figure 5a). Dinaciclib treatment also
led to reduced phosphorylation of the RALB target TBK1 and
increased cleavage of apoptotic effector, CASP3 (Figures 5b and c),
but did not alter the proportion of cells in the G0/G1 phase of the
cell cycle (Figure 5c). Dinaciclib potently reduced leukemic cell
viability with a half-maximal inhibitory concentration in the low
nanomolar range for a panel of genetically diverse human AML
cell lines (THP1, KG1, Kasumi-1, K562 and MV4-11; Figure 1d and
Supplementary Figure S4). To verify the RALB-dependent effects
of dinaciclib on AML cells, we rescued the clonogenic potential of
THP1 cells by ectopically expressing constitutively activated RALB
(Q72L)36 (Figure 5e). Notably, ectopic expression of constitutively
activated forms of other major Ras effectors, myristoylated AKT
(myrAKT) or CRAF 22W, did not effectively rescue leukemic colony
formation (Figure 5e).
Dinaciclib induces apoptosis in patient-derived AML samples
in vitro and has potent antileukemic activity in preclinical AML
models in vivo
We then evaluated effects of dinaciclib on primary patient-derived
AML samples. We previously found that primary AML samples
have increased levels of RALB-TBK1 signaling compared with
normal blood mononuclear cells from healthy mobilized periph-
eral blood donors.37 In vitro treatment of a panel of AML samples
with dinaciclib uniformly resulted in decreased phosphorylation of
TBK1 and increased cleavage of CASP3, while normal mono-
nuclear cells from healthy donors were relatively insensitive to
dinaciclib treatment (Figure 6). There was not a clear relationship
between the response to treatment and the clinical characteristics
of the samples (Supplementary Table S5).
To further evaluate the translational potential of our findings,
we tested the in vivo activity of dinaciclib against human AML cell
line mouse xenografts. Mice with established leukemia were
treated with five daily doses of 20 mg/kg dinaciclib or control
vehicle. A five-day regimen reduced the leukemic burden in
human THP1-luciferase mouse xenografts compared with controls
(Figure 7a). We then evaluated the activity of dinaciclib against
patient-derived AML mouse xenografts (PDX). Leukemic PDX mice
were treated with five daily doses of 20 mg/kg dinaciclib or
control vehicle. Treatment with dinaciclib led to a marked
reduction in bone marrow involvement by human AML cells and
a 2-log reduction in absolute leukemic burden compared with
control treated PDX mice (Figure 7b).
Inhibition of RALB activation potently suppresses leukemic colony
formation and prevents NRI AML relapse
To explore the therapeutic potential for inhibiting RALB activation
in relapsed NRI AMLs, we evaluated the activity of dinaciclib
against de novo NRD and relapsed NRI AMLs. Treatment of de novo
NRD AML and relapsed NRI AMLs with dinaciclib resulted in a
dose-dependent reduction in leukemic colony formation in the
low nanomolar range (Figure 8a). Similarly, inhibition of BCL2
family proteins with ABT-737 or ABT-199 suppressed the
clonogenic potential of de novo NRD AML and relapsed NRI AMLs
(Figure 8a), consistent with the established role of BCL2 proteins
to support cancer cell survival downstream of RALB.38
We then evaluated the in vivo activity of dinaciclib in human
preclinical AML mouse models. To increase the frequency of AML
relapse in the tNM model, we transferred a 1:1 ratio of de novo
NRD AML and relapsed NRI1 AML cells into recipient mice.
Leukemic mice were assigned to treatment with control vehicle,
Dox (to suppress NRAS(V12) expression), or dinaciclib (Figure 8b).
The leukemia initially regressed in Dox-treated mice, but mice
relapsed between 3 and 4 weeks despite continued Dox
treatment. Conversely, dinaciclib induced a prompt response in
leukemic mice, and none of the dinaciclib-treated mice relapsed
out to 40 days, further supporting the role of RALB activation in
relapse with NRI AML and demonstrating the therapeutic potential
of targeting this pathway.
DISCUSSION
In this study, we investigated potential mechanisms that bypass
the requirement for NRAS(V12) in AML and represent putative
mechanisms of resistance to therapeutically targeting oncogenic
NRAS. In the NRAS(V12)-addicted tNM AML mouse model, some
mice spontaneously relapsed with NRAS oncogene-independent
AML despite continued suppression of NRAS(V12) expression. The
spontaneous relapse seen after mimicking RAS oncogene-targeted
cancer therapy closely resembles the major clinical challenge for
targeted cancer therapies in general,15–22,39,40 and confirm that
NRAS(V12)-addicted AML cells can acquire alternative mechanisms
for maintained growth and survival and survive in the absence of
the NRAS oncogene. With renewed efforts to therapeutically target
oncogenic Ras proteins, our results have important implications
for anticipating therapeutic challenges for such treatment
strategies.41,42 Specifically, we found that relapsed AMLs devel-
oped an NRI mechanism to maintain signaling through RALB. The
ability of inhibition of RALB signaling to suppress the clonogenic
potential of relapsed NRI AML and to prevent AML relapse in
leukemic mice supports further investigation of this pathway as a
therapeutic target. Furthermore, the potent antileukemic effect of
inhibiting RALB signaling in human AML, including patient-
derived AML cells in vitro and in vivo, highlights the translational
potential for our findings.
There is mounting evidence that the activation and cellular
localization of Ral GTPase effector proteins have an important
role in Ras-driven transformation, proliferation, migration and
survival.43 Consistent with this, we recently demonstrated a key
role for RALB in AML cell survival.37 RALA or RALB activity are
essential for cancer cell proliferation in a murine KRAS-driven non-
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small-cell lung cancer model.44 While RALB has a central role in
innate immune signaling, chronically activated RALB associates
with SEC5 in the exocyst complex and activates the noncanonical
IκB kinase family member TBK1, a critical mediator of RALB’s
oncogenic activity.45 The mechanism by which the RALB-TBK1
axis supports cancer cell survival remains unclear and are
likely context and disease dependent, but have been shown to
involve regulators of normal innate immune signaling in several
pTBK1
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Figure 5. Dinaciclib inhibits RALB activation and has RALB-dependent antileukemic effects in human AML cell lines. (a) Western blot for RALB-
GTP, total RALB and GAPDH proteins in KG1 AML cells treated for 8 h with DMSO or dinaciclib (representative of three independent
experiments). (b) Phosphorylated TBK1 (pTBK1) levels in AML cells 24 h after treatment with dinaciclib (representative of three independent
experiments). (c) Percentage of AML cells with cleaved PARP (cPARP+) (top) and proportion of G0/G1 cells (bottom) 24 h after treatment with
dinaciclib determined by flow cytometry (n= 3 independent experiments, error bars= s.e.m., *Po0.05). (d) MTS viability analysis of AML cell
lines 72 h after dinaciclib treatment and calculated half-maximal inhibitory concentrations (IC50) (n= 3–5 independent experiments, error bars
are not included for clarity of presentation and are included in Supplementary Figure 4). (e) Relative leukemic colony formation (L-CFC) of
THP1 transduced with RALB(Q72L), myristoylated AKT (myrAKT), CRAF 22W or control vector (BFP) 24 h after treatment with dinaciclib relative to
DMSO-treated controls (n= 3 independent experiments, error bars= 1 s.d., *Po0.05).
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models.38,46 A large-scale synthetic lethal RNAi screen uncovered a
critical role for TBK1 in KRAS-driven transformation of epithelial
cells through activation of nuclear factor-κB antiapoptotic signals
involving REL and BCL-xL.38 We found that upregulation of Cdk5
and Rgl2, activators of RALB signaling,34,35 as well as increased
Ralb expression was associated with NRI activation of RALB-TBK1
signaling in relapsed AMLs. Activation of RALB signaling and
upregulation of components of the nuclear factor-κB transcrip-
tional complex were accompanied by an altered balance of
pro- and antiapoptotic mediators, consistent with previous reports
suggesting that nuclear factor-κB signaling downstream of RALB
supports cancer cell survival.38,45 We have previously shown that
RALB enhances expression of BCL2 in AML, providing a potential
mechanism by which RALB drives NRI AML relapse.37 Consistent
with this, BCL2 family inhibitors to suppressed the clonogenic
potential of relapsed NRI AML cells; however, the precise
mechanisms that promote AML cell survival downstream of RALB
remain to be elucidated.
While targeting RALB activation with dinaciclib demonstrated
potent RALB-dependent antileukemic effects on AML cells, we
cannot exclude the contribution of RALB-independent effects. It is
possible that dinaciclib-mediated inhibition of CDK1, another
protein that was enriched in relapse NRI AMLs, or CDK9, an
alternate survival pathway for MLL-rearranged AMLs,47 contributes
to the antileukemic activity of dinaciclib. In fact, drugs that target
multiple pathways may reduce the ability of AML cells to coopt
alternate resistance pathways. Our findings support the further
investigation of the critical targets of dinaciclib in AML. New small
molecules that directly inhibit Ral function may provide additional
tools to study the role and therapeutic potential of RALB signaling
in AML as they become available.48
Our data also identified several other potential mechanisms that
may bypass RAS oncogene dependence of AML cells. The altered
balance of pro- and antiapoptotic mediators in relapsed NRI AML
cells that could be a direct or indirect result from enhanced RALB
signaling warrants further investigation. YAP, a mediator of the
Hippo signaling pathway that has been shown to mediate
resistance to inhibition of MAPK signaling and promote Kras
oncogene independence in oncogenic pancreatic cancer,24,25 was
enriched in relapsed NRI AMLs. Overall, the broad deregulation of
signaling and gene transcription observed provides a foundation
for the ongoing rational development of targeted treatment
approaches designed to mitigate or prevent relapse after Ras
targeted treatment strategies.
This work provides important insight into the mechanisms of
response and resistance to targeted cancer treatment approaches
in general, and particularly for renewed efforts to therapeutically
target Ras signaling.41 Furthermore, our results support further
characterization of RALB signaling as a key mediator of survival
and NRAS-independent relapse in AML and as a valid therapeutic
target.
MATERIALS AND METHODS
Mouse studies
All mouse studies were approved by the University of Minnesota
Institutional Animal Care and Use Committee. Roughly equal number of
male and female mice were used for all experiments and evenly allocated
to experimental groups without systematic randomization or blinding.
Group sizes were determined based on the number of mice required for
80% power to detect a difference in the mean AML burden of at least 1.5 s.d.
between experimental and control groups with Po0.05 using a t-test.
For leukemic cell transplantation, 2 × 106 tNM AML cells, 4 × 106 THP1-
luciferase AML cells or 2 × 106 patient-derived AML cells were injected via
tail vein into 6–10-week-old recipient mice. Severe combined immuno-
deficiency (SCID) beige (Charles River, Burlington, MA, USA) mice did not
receive any preconditioning before murine AML transplantation. NRG or
NRGS (Jackson Labs, Bar Harbor, ME, USA) mice received 375 cGy from an
X-ray source 24 h before human AML transplantation. Peripheral blood was
obtained by retro-orbital blood sampling and leukocyte counts were
monitored using a Hemavet 950 (Drew Scientific, Miami Lakes, FL, USA).
THP1-luciferase mice were monitored using an IVIS 100 Imaging System
(Perkin-Elmer, Waltham, MA, USA). PDX mice were monitored by flow
cytometry of peripheral blood stained for human CD45 and human CD33.
Doxycycline-treated mice were given 4 mg intraperitoneally doxycycline
(Sigma-Aldrich, Saint Louis, MO, USA) followed by 5 mg/ml in their water.
Inhibitors
Dinaciclib, ABT-737 and ABT-199 were purchased from Selleck Chemicals
(Houston, TX, USA) and reconstituted in dimethyl sulfoxide (DMSO). For
in vitro studies inhibitors were diluted in the growth medium. For in vivo
studies dinaciclib was diluted in 20% hydroxypropyl-β-cyclodextrin and
administered intraperitoneally.
Leukemia colony-forming cell assay
NRD and NRI AML cells were cultured in RPMI-1640 (Lonza, Basel,
Switzerland) with 10% fetal bovine serum (Atlas Biologicals, Fort Collins,
CO, USA) with or without 1 μg/ml doxycycline (Sigma-Aldrich) for 48 h or
inhibitors for 24 h and then plated in IMDM (Lonza) with 30% fetal bovine
serum, 1.275% methylcellulose (R&D Systems, Minneapolis, MN, USA) and
2 ng/ml murine GM-CSF (R&D Systems). Human AML cells were treated
with inhibitors for 24 h and then plated in MethoCult H4034 (Stem Cell
Technologies, Vancouver, BC, Canada). Colonies were scored after 7–14 days
on an inverted microscope.
Western blotting and RALB-GTP assay
Protein lysates were run on 10% polyacrylamide gel electrophoresis gels
and transferred to a PVDF using the NuPAGE and iBlot Systems (Life
Technologies, Carlsbad, CA, USA). RALB-GTP levels were determined using
the RALB Activation Assay Kit (EMD Millipore, Billerica, MA, USA). Blots were
blocked and stained according to antibody manufacturer’s recommenda-
tions. Blots were developed using the SuperSignal West Pico ECL (Thermo
Fisher, Minneapolis, MN, USA) or Advansta Quantum ECL Kit (Advansta,
Figure 6. Dinaciclib inhibits RALB-TBK1 signaling and induces
apoptosis in primary patient-derived AML cells. (Top) Relative mean
fluorescence intensity (MFI) of phosphorylated TBK1 (pTBK1) and
(bottom) percentage of cells with cleaved caspase-3 (cCASP3+) in
individual AML patient samples (AML, n= 5) or mononuclear cells
from healthy granulocyte-colony stimulating factor (G-CSF) mobi-
lized peripheral blood donors (MPBs, n= 3) after 24 h treatment with
dinaciclib measured by flow cytometry.
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Menlo Park, CA, USA) and signals were quantified using the LI-COR Imaging
System (LI-COR Biosciences, Lincoln, NE, USA).
Flow cytometric analysis
Flow cytometric analysis was performed as described previously.49 Briefly,
for intracellular antigens cells were fixed with 2% paraformaldehyde
(Electron Microscopy Sciences, Hatfield, PA, USA) and permeabilized with
90% methanol (Sigma-Aldrich). Cells were stained with antibodies
according to the manufacturer’s recommendations. Cells were analyzed
on an LSR II or Fortessa Digital Flow Cytometer (BD Biosciences, San Jose,
CA, USA) and analyzed using the FlowJo software (Ashland, OR, USA).
Antibodies
For western blotting, NRAS (F155) mouse monoclonal IgG1 (sc-31) and
HRP-conjugated secondary antibodies were purchased from Santa Cruz
Biotechnology (Dallas, TX, USA); BCL-xL rabbit polyclonal (2762) and
GAPDH (14C10) rabbit monoclonal (2118) were purchased from Cell
Signaling Technologies (Danvers, MA, USA); and BCL2 mouse monoclonal
(610538) was purchased from BD Biosciences. For flow cytometry, c-MYC
(9E10) Alexa Fluor 700, BAD (Y208), BAX (E63), BCL2 (E17), BCL-xL (E18) and
BIM (Y36), and MCL1 (Y37) were purchased from Abcam/Epitomics
(Cambridge, MA, USA); phospho-4EBP1 (Thr46) and phospho-mTOR
(Ser2448) were purchased from Thermo Fisher; cleaved caspase-3
(Asp175, D3E9) phycoerythrin, cleaved PARP (Aps214, 5A1E) Alexa Fluor
647, phospho-4E-BP1 (Thr37/46, 236B4) Alexa Fluor 647, phospho-AKT
(Ser473, D9E) Alexa Fluor 488, phospho-p44/p42 MAPK (Erk1/2, Thr202/
Tyr204, D13.14.4E) phycoerythrin, BCL-xL (54H6), BIM (C34C5), IkBa (L35A5),
PTEN (138G6), phospho-JNK (Thr183/Tyr185, G9), phospho-S6 (Ser235/236)
and phospho-TBK1 (Ser172, D52C2) phycoerythrin were purchased
from Cell Signaling Technologies; PUMA (RB1353-RB1354) was purchased
from Novus Biologicals (Littleton, CO, USA); and phospho-TBK1 (pS172,
J133-587) Alexa Fluor 488, cleaved PARP (Asp214), Ki67 (B56), phospho-
AKT (pS473, M89-61), phospho-STAT5 (pY694, 47), human CD45 (2D1) FITC
and human CD33 (P67.6) phycoerythrin were purchased from BD
Biosciences.
Reverse-phase protein arrays
Total splenocytes were harvested from leukemic mice, snap frozen in liquid
nitrogen and sent to the MD Anderson RPPA Core Facility for analysis.
Briefly, protein lysates were serially diluted and arrayed on nitrocellulose-
coated slides using an Aushon 2470 Arrayer (Aushon BioSystems, Billerica,
MA, USA). The slides were scanned, analyzed and quantified using Array-
Pro Analyzer (Tecan Group Ltd, Männedorf, Switzerland). Protein concen-
trations were normalized by median polish, which was corrected across
samples by the linear expression values using the median expression levels
of all antibody experiments to calculate a loading correction factor for each
sample. Normalized protein values were used to evaluate differential target
levels between NRD and NRI samples using a Benjamini–Hochberg-
corrected q-value of ⩽ 0.05.
Next-generation RNA sequencing
Total splenocytes were harvested from leukemic mice and RNA was
extracted using the RNeasy Midi Kit (Qiagen, Hilden, Germany). RNA
samples were quantified, quality checked and analyzed using the Illumina
HiSeq 2000 (Illumina, San Diego, CA, USA) at the University of Minnesota
Genomics Core Facility. Raw data was mapped to the mouse mm9 genome
using TOPHAT2 suite.50 Differential expression between NRD and NRI
samples was determined using Cuffdiff.51 R (R core Team 2013) was used
to visualize expression data. Genes with RNAseq expression variation over
0.2 were log transformed and mean centered. The resulting data was
clustered using Pvclust package with correlation as distance metric and
average clustering method.52 Differential transcript expression was defined
dinaciclib
vehicle
Day 6 Radiance
Figure 7. Dinaciclib has potent antileukemic activity in preclinical AML models including patient-derived AML xenograft (PDX) mice. (a) Total
flux in human THP1-luciferase mouse xenografts treated daily for 5 days with control vehicle or 20 mg/kg dinaciclib (bars=mean± 1 s.d.,
*Po0.05) and radiance images on day 6 after completion of treatment. (b) Percentage (left) and absolute number (right) of human CD45 and
human CD33-double-positive AML cells in the hindlimb bone marrow from NRGS PDX mice (AML2 sample from Figure 6) after 5 daily
treatments with 20 mg/kg dinaciclib or control vehicle (bars=mean± 1 s.d.).
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using a Benjamini–Hochberg-corrected q-value of ⩽ 0.01. The data
discussed have been deposited in NCBI's Gene Expression Omnibus
(GSE87870).
Cell culture and primary AML samples
Cell lines were originally obtained from ATCC or DSMZ, maintained under
standard cell culture conditions, tested monthly for mycoplasma
contamination and authenticated by STR analysis at the University of
Arizona Genomics Core. De-identified mobilized peripheral blood and AML
patient samples were obtained after informed consent according to
protocols approved by the University of Minnesota Institutional Review
Board. Primary AML samples were cultured in IMDM (Thermo Fisher)
supplemented with 20% fetal bovine serum (Atlas Biologicals, Fort Collins,
CO, USA), 100 μM 2-mercaptoethanol (Sigma-Aldrich), 1% GlutaMAX
(Thermo Fisher) and 10 ng/ml each of stem cell factor, interleukin-3,
interleukin-6, FLT3 (FMS-related tyrosine kinase 3) ligand and thrombo-
poietin (all from R&D Systems).
Viable cell enumeration
Viable cell numbers were determined using the CellTiter 96 Aqueous Non-
Radioactive Cell Proliferation Assay (Promega, Madison, WI, USA). Half-
maximal inhibitory concentrations were calculated using CalcuSyn 2.0
(BioSoft, Cambridge, UK).
Lentiviral transduction of AML cells
Lentiviral expression vectors were generated using the Gateway cloning
system (Thermo Fisher). BFP-expressing lentiviral vectors were generated
from a previously described backbone,53 by replacing eGFP with eBFP2 and
luciferase with RALB(Q72L) (from Channing Der via Addgene plasmid no.
19721), myrAKT (from John Ohlfest) or CRAF W22 (from Channing Der via
Addgene plasmid no. 12593). Vesicular stomatitis virus-G-pseudotyped
lentivirus was produced by co-transfecting a 1:2:3 ratio of pMD2.G,
pCMVDR8.2 (both from Dider Trono via Addgene nos 12259 and 8455) and
lentiviral expression vector into HEK293 cells using X-treme Gene HP
(Roche, Basel, Switzerland). Viral supernatant was harvested after 48 h,
filtered and used for transduction. Target cells were transduced by
coculture with viral supernatant and 5 μg/ml polybrene overnight.
Statistics
Unless otherwise indicated, statistical differences between two groups were
determined using an unpaired, two-tailed t-test corrected for multiple
comparisons using the Holm–Sidak method with PRISM software (GraphPad,
La Jolla, CA, USA). Statistical significance was defined as P⩽ 0.05.
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